Page 1/1

Vaccines

Intercell Raises Authorized Capital

The Management Board of the Austrian biotechnology company is authorized to increase the share capital up to a nominal amount of € 855,000.00.

December 16, 2010

Serious setback for Intercell

The Vienna vaccine manufacturers has to terminate a research project unexpectedly at a late stage. Heavy losses are expected for this year.

December 14, 2010

Intercell AG: Losses Doubled, Positive Outlook

Today, Vienna-based Intercell AG announced its financial results for the third quarter of 2010 and presented changes to the Management Board.

November 9, 2010
Fast News Search